Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 20/20 | 1.00 |
| ▸ | EPM2A | O95278 | 1/20 | 0.72 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.72 |
| ▸ | PTPRG | P23470 | 1/20 | 0.72 |
| ▸ | ACP1 | P24666 | 1/20 | 0.72 |
| ▸ | PTPN3 | P26045 | 1/20 | 0.72 |
| ▸ | PTPRM | P28827 | 1/20 | 0.72 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.72 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.72 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.72 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.72 |
| ▸ | PTPRS | Q13332 | 1/20 | 0.72 |
| ▸ | PTPN14 | Q15678 | 1/20 | 0.72 |
| ▸ | PTPN21 | Q16825 | 1/20 | 0.72 |
| ▸ | UBLCP1 | Q8WVY7 | 1/20 | 0.72 |
| ▸ | DUSP23 | Q9BVJ7 | 1/20 | 0.72 |
| ▸ | SSU72 | Q9NP77 | 1/20 | 0.72 |
| ▸ | CDC14A | Q9UNH5 | 1/20 | 0.72 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.72 |
| ▸ | DUSP10 | Q9Y6W6 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30367246 | 1.00 | PTPN11 (1.00) | PTPN11EPM2APTPN1PTPRGACP1 | |
| SCHEMBL16376122 | 0.92 | PTPN11 (1.00) | PTPN11EPM2APTPN1PTPRGACP1 | |
| SCHEMBL16376231 | 0.91 | PTPN11 (1.00) | PTPN11EPM2APTPN1PTPRGACP1 | |
| SCHEMBL17669825 | 0.91 | PTPN11 (1.00) | PTPN11EPM2APTPN1PTPRGACP1 | |
| SCHEMBL16375397 | 0.90 | PTPN11 (1.00) | PTPN11EPM2APTPN1PTPRGACP1 | |
| SCHEMBL30367054 | 0.90 | PTPN11 (1.00) | PTPN11EPM2APTPN1PTPRGACP1 | |
| SCHEMBL18323102 | 0.90 | PTPN11 (0.85) | PTPN11EPM2APTPN1PTPRGACP1 | |
| SCHEMBL16375402 | 0.90 | PTPN11 (1.00) | PTPN11EPM2APTPN1PTPRGACP1 | |
| SCHEMBL18323107 | 0.90 | PTPN11 (0.81) | PTPN11EPM2APTPN1PTPRGACP1 | |
| SCHEMBL18323112 | 0.90 | PTPN11 (0.81) | PTPN11EPM2APTPN1PTPRGACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110423212-B | Hydroxy indole carboxylic acid-based inhibitors of SHP2 | 美国印第安纳大学研究和技术公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-105142634-B | Oxindole carboxylic acid-based inhibitors of oncogenic protein tyrosine phosphatase-2(SHP2) comprising Src homology-2domain | 美国印第安纳大学研究和技术公司 | 2020-06-12 | — | — | CN | disclosed |
| US-20190000801-A1 | METHODS OF TREATING AUTOIMMUNE AND/OR GLOMERULONEPHRITIS-ASSOCIATED DISEASES USING SHP2 INHIBITORS | INDIANA UNIV RESEARCH AND TECHNLOGY CORPORATION (US) | 2019-01-03 | — | — | US | disclosed |
| US-20180071252-A1 | METHODS OF TREATING AUTOIMMUNE AND/OR GLOMERULONEPHRITIS-ASSOCIATED DISEASES USING SHP2 INHIBITORS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20180071252-A1 | METHODS OF TREATING AUTOIMMUNE AND/OR GLOMERULONEPHRITIS-ASSOCIATED DISEASES USING SHP2 INHIBITORS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2018-03-15 | — | — | US | disclosed |
| US-9844535-B2 | SHP2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using SHP2 inhibitors | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-12-19 | — | — | US | disclosed |
| US-9844535-B2 | SHP2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using SHP2 inhibitors | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-12-19 | — | — | US | disclosed |
| US-20160374988-A1 | SHP2 INHIBITORS AND METHODS OF TREATING AUTOIMMUNE AND/OR GLOMERULONEPHRITIS-ASSOCIATED DISEASES USING SHP2 INHIBITORS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2016-12-29 | — | — | US | disclosed |
| US-9522881-B2 | Hydroxyindole carboxylic acid based inhibitors for oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-12-20 | — | — | US | disclosed |
| US-9522881-B2 | Hydroxyindole carboxylic acid based inhibitors for oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-12-20 | — | — | US | disclosed |
| US-9522881-B2 | Hydroxyindole carboxylic acid based inhibitors for oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-12-20 | — | — | US | disclosed |
| US-20160102054-A1 | HYDROXYINDOLE CARBOXYLIC ACID BASED INHIBITORS FOR ONCOGENIC SRC HOMOLOGY-2 DOMAIN CONTAINING PROTEIN TYROSINE PHOSPHATASE-2 (SHP2) | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2016-04-14 | — | — | US | disclosed |
| US-20160102054-A1 | HYDROXYINDOLE CARBOXYLIC ACID BASED INHIBITORS FOR ONCOGENIC SRC HOMOLOGY-2 DOMAIN CONTAINING PROTEIN TYROSINE PHOSPHATASE-2 (SHP2) | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2016-04-14 | — | — | US | disclosed |
| US-20160102054-A1 | HYDROXYINDOLE CARBOXYLIC ACID BASED INHIBITORS FOR ONCOGENIC SRC HOMOLOGY-2 DOMAIN CONTAINING PROTEIN TYROSINE PHOSPHATASE-2 (SHP2) | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2016-04-14 | — | — | US | disclosed |
| WO-2015003094-A2 | SHP2 INHIBITORS AND METHODS OF TREATING AUTOIMMUNE AND/OR GLOMERULONEPHRITIS-ASSOCIATED DISEASES USING SHP2 INHIBITORS | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2015-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071252-A1 | METHODS OF TREATING AUTOIMMUNE AND/OR GLOMERULONEPHRITIS-ASSOCIATED DISEASES USING SHP2 INHIBITORS | PTPRJ, PTPRCAP, PTPRC | PTPN11 28/4885EPM2A 1897/4885PTPN1 14/4885 |
| US-20160102054-A1 | HYDROXYINDOLE CARBOXYLIC ACID BASED INHIBITORS FOR ONCOGENIC SRC HOMOLOGY-2 DOMAIN CONTAINING PROTEIN TYROSINE PHOSPHATASE-2 (SHP2) | SRC, PTPRCAP, PTPRJ | PTPN11 33/4885EPM2A 1637/4885PTPN1 20/4885 |
| US-20190000801-A1 | METHODS OF TREATING AUTOIMMUNE AND/OR GLOMERULONEPHRITIS-ASSOCIATED DISEASES USING SHP2 INHIBITORS | PTPRJ, PTPRCAP, PTPRC | PTPN11 28/4885EPM2A 1897/4885PTPN1 14/4885 |
| US-20160374988-A1 | SHP2 INHIBITORS AND METHODS OF TREATING AUTOIMMUNE AND/OR GLOMERULONEPHRITIS-ASSOCIATED DISEASES USING SHP2 INHIBITORS | PTPRJ, PTPRCAP, PTPN2 | PTPN11 20/4885EPM2A 1920/4885PTPN1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.